ImmunoPrecise Antibodies Ltd. is a public company listed on the TSX Venture Exchange (TSXV: IPA) located in Victoria, British Columbia, Canada and preeminent supplier of custom antibodies to the global research industry and industrial community. Our dedication to advancing antibody development has resulted in cutting-edge immunological innovations. With over 25 years of experience in the custom antibody business, ImmunoPrecise provides high customer satisfaction through a customized professional approach.
ImmunoPrecise is comprised of experienced research and development scientists and encompasses a wide range of distinctive competencies, including innovative technologies required in the production of monoclonal and polyclonal antibodies. We pride ourselves on our high customer satisfaction and our clients have grown accustomed to receiving very thorough and professional service. We customize your project to generate antibodies that meet your specific needs. Our clients include: scientists in the biotech and pharmaceutical sector, academic researchers and those employed by government.
Since its inception in 1989, ImmunoPrecise has been serving clinical research and biological markets worldwide. With its beginnings in the Biochemistry/Microbiology department at the University of Victoria, ImmunoPrecise expanded and built a new Hybridoma Facility, at the Vancouver Island Technology Park (VITP) in 2005.
Robert Beecroft, Chief Technical Officer and Founder, has implemented 3 key methodologies that have allowed ImmunoPrecise to be set apart from other antibody companies: 1) the Rapid Prime immunization strategy in mice; 2) Single-Step cloning for HAT selection of hybridomas and 3) RMAT –recombinant monoclonal antibody technology for the generation of rabbit monoclonal antibodies.
ImmunoPrecise uses proprietary and innovative inoculation and cloning technologies and established expertise to produce mAbs significantly faster than traditional methods of antibody production and has used these capacities to produce hundreds of mAbs, many of which are now being sold commercially through industry partners.
We have an in-house animal care unit, tissue culture facility and a molecular facility.